Monte Rosa Therapeutics, Inc. (GLUE) vs InMode Ltd. (INMD)

A side-by-side comparison of Monte Rosa Therapeutics, Inc. and InMode Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Monte Rosa Therapeutics, Inc. logo
GLUE
Monte Rosa Therapeutics, Inc.
$868M
$10.28HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
InMode Ltd. logo
INMD
InMode Ltd.
$806M
$14.02HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT

Total return — GLUE vs INMD

growth of $100 · dividends reinvested · last 5y
GLUE -51.5% (-13.5%/yr)INMD -70.2% (-21.5%/yr)GLUE compounded faster over this window
050100150200Start $10020222023202420252026$48$30
GLUE INMD

GLUE vs INMD: by the numbers

  • •GLUE is the larger company ($868M vs $806M market cap).
  • •INMD is profitable (20.69% net margin) while GLUE runs a net loss (-560.85%).

Metrics side by side

Valuation

MetricGLUEINMD
P/E ratioN/A11.39
Forward P/EN/A10.81
PEG ratioN/A1.15
P/S ratio30.232.15
P/B ratio1.781.28
EV / EBITDAN/A5.92
FCF yieldN/A10.86%

Profitability

MetricGLUEINMD
Gross margin92.94%76.52%
Operating margin-43.83%18.47%
Net margin-560.85%20.69%
ROE-33.06%12.32%
ROIC-28.69%9.20%

Growth (annualized)

MetricGLUEINMD
Revenue CAGR (5Y)N/A5.42%
EPS CAGR (5Y)N/A6.87%
FCF CAGR (5Y)N/A1.36%
Total return CAGR (5Y)-12.32%-27.48%

Frequently asked

Is GLUE or INMD more profitable?
INMD runs the higher net margin — GLUE at -560.85% versus INMD at 20.69%.
How have GLUE and INMD total returns compared?
Over the past 5 years, GLUE delivered -12.32% and INMD delivered -27.48% annualized total return. Past performance doesn't predict future results.

Go deeper

Full GLUE analysisFull INMD analysisInteractive comparison tool

Dig into the metrics

InMode P/E ratioMonte Rosa Therapeutics ROEInMode ROEMonte Rosa Therapeutics operating marginInMode operating marginMonte Rosa Therapeutics revenue growthInMode revenue growthMonte Rosa Therapeutics free cash flowInMode free cash flow

Monte Rosa Therapeutics & InMode appear in these rankings

Highest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.